Echelon Wealth Partners Comments on Medexus Pharmaceuticals Inc.’s Q1 2025 Earnings (TSE:MDP)

Medexus Pharmaceuticals Inc. (TSE:MDPFree Report) – Equities researchers at Echelon Wealth Partners issued their Q1 2025 earnings estimates for shares of Medexus Pharmaceuticals in a note issued to investors on Thursday, February 8th. Echelon Wealth Partners analyst S. Quenneville anticipates that the company will post earnings per share of $0.03 for the quarter. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.34 per share. Echelon Wealth Partners also issued estimates for Medexus Pharmaceuticals’ Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at $0.08 EPS and Q4 2025 earnings at $0.12 EPS.

Medexus Pharmaceuticals (TSE:MDPGet Free Report) last posted its quarterly earnings results on Wednesday, February 7th. The company reported C($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.10 by C($0.13). The firm had revenue of C$34.33 million for the quarter, compared to analysts’ expectations of C$42.33 million. Medexus Pharmaceuticals had a return on equity of 26.14% and a net margin of 5.08%.

Medexus Pharmaceuticals Trading Down 4.3 %

MDP stock opened at C$1.79 on Monday. Medexus Pharmaceuticals has a 12-month low of C$1.12 and a 12-month high of C$3.53. The company has a market cap of C$43.78 million, a price-to-earnings ratio of 5.26 and a beta of 1.75. The firm has a 50 day moving average of C$2.27 and a 200-day moving average of C$2.44.

Medexus Pharmaceuticals Company Profile

(Get Free Report)

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

Read More

Earnings History and Estimates for Medexus Pharmaceuticals (TSE:MDP)

Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with's FREE daily email newsletter.